Synthesis and biological evaluation of the Fluoro analog of Romidepsin with improved selectivity for class I histone deacetylases (HDACs)
Bioorganic Chemistry · 2025
DOI: 10.1016/j.bioorg.2025.108348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Xinluo Song und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Fudan University; 826 Zhangheng Road, Pudong Zone, Shanghai 201203, China. Hauptthemen laut MEDLINE: Depsipeptides, Histone Deacetylase Inhibitors, Histone Deacetylases, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China, Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Selective inhibition of Class I HDACs has emerged as a promising approach for cancer therapy. Building on our previous work with Largazole (a member of the natural depsipeptide family), we have applied a similar fluorination modification to Romidepsin and synthesized its fluoro analog (12) in 12 steps. This analog exhibits potent inhibitory activity against Class I HDACs but shows no inhibitory effect on HDAC6, confirming its selectivity as a Class I HDAC inhibitor (IC50 HDAC1 0.95 nM, HDAC2 0.86, HDAC 3 1.1 nM, HDAC8 4.2 nM, HDAC6 > 103 nM). Compared with Romidepsin, compound 12 demonstrates significant growth inhibition in two cancer cell lines (NCI-H1975 and HT29) while exhibiting markedly less growth inhibition in two normal cell lines (WRL-68 and HEK293). Further studies reveal that 12 is capable of blocking the cell cycle and inducing apoptosis, thereby exerting anticancer activity. Moreover, 12 possesses metabolic stability comparable to Romidepsin. In a mouse model, 12 demonstrates strong in vivo antitumor efficacy similar to that of Romidepsin, yet with significantly reduced toxicity. These findings support the potential of this fluoro analog as a highly selective Class I HDAC inhibitor and highlight its promise as a superior alternative to Romidepsin for further development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Fudan University; 826 Zhangheng Road, Pudong Zone, Shanghai 201203, China.
- Shanghai Forxine Pharmaceutical Co., Ltd; Building 9, 1835 Duhui Road, Minhang Zone, Shanghai 201108, China.
Förderung
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
- Shanghai Municipal Health Commission
Zitieren
APA
Song, X., Wang, H., Gao, Y., Zhang, W., & Lei, X. (2025). Synthesis and biological evaluation of the Fluoro analog of Romidepsin with improved selectivity for class I histone deacetylases (HDACs). Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.108348
Vancouver
Song X, Wang H, Gao Y, Zhang W, Lei X. Synthesis and biological evaluation of the Fluoro analog of Romidepsin with improved selectivity for class I histone deacetylases (HDACs). Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.108348
BibTeX
@article{Song2025,
author = {Song, Xinluo and Wang, Hanqi and Gao, Ya and Zhang, Wei and Lei, Xinsheng},
title = {Synthesis and biological evaluation of the Fluoro analog of Romidepsin with improved selectivity for class I histone deacetylases (HDACs)},
journal = {Bioorganic Chemistry},
year = {2025},
doi = {10.1016/j.bioorg.2025.108348}
}
EUVIMED